Spleen tyrosine kinase (Syk) is an essential mediator of B-cell receptor signaling in normal and transformed B-cells. GS-9973 is an orally bioavailable, small-molecule, selective inhibitor of Syk.
Idelalisib is a first-in-class, selective, oral inhibitor of PI3Kδ that reduces proliferation, enhances apoptosis, and inhibits homing and retention of malignant B cells in lymphoid tissues. Furman and colleagues conducted a phase 3 trial that evaluated and compared the efficacy and safety of idelalisib plus rituximab (IDELA + R) and placebo plus rituximab (placebo + R).
Based on phase 1/2 trials, single-agent ibrutinib induces an overall response rate (ORR) of 71% in relapsed chronic lymphocytic leukemia (CLL). To enhance responses to ibrutinib in patients with high-risk CLL, a phase 2 study of ibrutinib in combination with rituximab was conducted.
Brown and colleagues reported final results from a phase 1b study of ibrutinib combined with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Led by Farooqui and colleagues, this investigator-initiated phase 2, single-center trial of ibrutinib monotherapy prospectively evaluated the role of ibrutinib in patients with chronic lymphocytic leukemia (CLL), with and without deletion 17p.
Bruton’s tyrosine kinase (BTK) plays a critical role in chronic lymphocytic leukemia (CLL) cell survival by modulating B-cell receptor signaling. Ibrutinib, a first-in-class oral inhibitor of BTK that was recently approved for use in mantle cell lymphoma, has been shown to inhibit proliferation, migration, and adhesion in CLL cells.
In this observational, retrospective study that was conducted in Europe, the primary objective was to understand the safety profile of ofatumumab when it was administered outside of clinical trials to patients with previously treated chronic lymphocytic leukemia (CLL).
Although chlorambucil (Clb) remains a standard option for elderly patients with chronic lymphocytic leukemia (CLL), more effective and tolerable treatment choices are needed. Compared with rituximab, ofatumumab (OF) demonstrated superior preclinical activity in CLL cells and has demonstrated clinical activity as monotherapy in patients with refractory CLL.
Eichhorst and colleagues conducted an international phase 3 study to evaluate the efficacy and tolerability of bendamustine and rituximab (BR) compared with fludarabine, cyclophosphamide, and rituximab (FCR) in first-line therapy of physically fit patients with chronic lymphocytic leukemia (CLL), who did not have a chromosome deletion 17p.
Obinutuzumab is a novel, glycoengineered, type II CD20 monoclonal antibody designed to increase direct and antibody-dependent cellular cytotoxicity. Early phase 1/2 studies in patients with chronic lymphocytic leukemia (CLL) demonstrated single-agent activity with treatment-related neutropenia.
Page 2 of 4
Results 11 - 20 of 37
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME